FORM 4

UNITED STATES SECU

Washington, D.C. 20549

| ΚI | HES | AND | EXC | HAN | JE (| COM | IMIS: | SIO |
|----|-----|-----|-----|-----|------|-----|-------|-----|
| | | | | | | | | |

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| .(0). 0 | ee msaacaon | | | | | | | | | | | | | | | | | | |
|--|---|----------------|--------------|-------------------------------|---|---|---------|--|--------|---|----------|--|---|--|---------------|---|---|------------|---------|
| Name and Address of Reporting Person* Driver Stephen Devid | | | | | | 2. Issuer Name and Ticker or Trading Symbol AN2 Therapeutics, Inc. [ANTX] | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | |
| <u>Prior Stephen David</u> | | | | | | | | | | | | | Director 10% O | | | | | | |
| - | | | | | | | | | | | | | | 1 | Office | er (give title | | Other (s | specify |
| (Last) | (F | rirst) (f | Middle) | | Date of Earliest Transaction (Month/Day/Year) | | | | | | | | | | chief Strat | toory (| , | | |
| C/O AN | 2 THERA | PEUTICS, INC. | | | 01/03/2025 | | | | | | | | | • | omer Suar | legy (| Officei | | |
| 1800 EL CAMINO REAL, SUITE D | | | | | | | | | | | | | | | | | | | |
| | CHIMITYO | TELLE, SOTTE I | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | |
| (Street) | | | | | 4. II Americinent, Date of Original Filed (Month/Day/ fear) | | | | | | | | Line) | | | | | | |
| l ` ′ | PARK C | Α 9 | 4027 | | | | | | | | | 1 | Form filed by One Reporting Person | | | | | | |
| MENTE | Triffic C | , | 1027 | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | |
| (O:t-) | /5 | N-4-) /- | 7 : \ | | | | | | | | | | | | Perso | on | | | |
| (City) | (8 | State) (Z | Zip) | | | | | | | | | | | | | | | | |
| | | Table | I - No | n-Deriva | tive S | ecur | ities A | cqu | uired, | Dis | posed of | , or E | Benef | icially | y Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | | Execution Date, | | е, | 3. 4. Securities Acquired Disposed Of (D) (Instr. 8) | | | | | Securities F Beneficially (Owned Following (| | Form (D) o | n: Direct or Indirect nstr. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | Ī | Code | v | Amount (A) or (D) | | or Pr | ice | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) | |
| Common Stock 01/03/2 | | | | | 025 | | | | S | | 2,029(1) | D | \$ | 1.341 | 33 | ,313(2) | | D | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any | | on Date, | 4. Transa Code (I 8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) | | | | 9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | y | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | | | | | Amou or | nt | | | | | |

Explanation of Responses:

- 1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025.
- 2. Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

Exercisable

Date

(D)

/s/ Lucy Day, Attorney-in-Fact 01/07/2025 for Stephen David Prior

** Signature of Reporting Person Date

Title

Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.